Table 5.
The AUROCs and optimal cut-offs for LSM according to ALT levels.
| ALT levels | AUROC (95% CI) | Cut off (kPa) | Se (%) | Sp (%) | PPV (%) | NPV (%) | PLR | NLR | DA (%) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Significant fibrosis | ≤1 ULN (n = 107) | 0.86 (0.78–0.92) | 6 | 83 | 88 | 81 | 89 | 6.91 | 0.20 | 82 |
| 1–2 ULN (n = 81) | 0.84 (0.74–0.91) | 6.5 | 74 | 89 | 93 | 63 | 6.67 | 0.29 | ||
| Cirrhosis | ≤1 ULN (n = 107) | 0.88 (0.80–0.93) | 7.8 | 75 | 82 | 35 | 96 | 4.19 | 0.30 | 86 |
| 1–2 ULN (n = 81) | 0.98 (0.93–1.00) | 10.2 | 94 | 95 | 83 | 98 | 20.31 | 0.07 |
AUROC, area under the receiver operating characteristic curve; LSM, liver stiffness measurement; ALT, alanine transaminase; CI, confidence interval; Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DA, diagnostic accuracy; Significant fibrosis, METAVIR F2-F4; Cirrhosis, METAVIR F4.